Total Synthesis and Biological Mode of Action of Largazole: A Potent Class I Histone Deacetylase Inhibitor
Open accessThe DOI matches its Crossref record; 32 of the 33 references it cites were found in a registry or an index.
Abstract
The efficient total synthesis of the recently described natural substance largazole (1) and its active metabolite largazole thiol (2) is described. The synthesis required eight linear steps and proceeded in 37% overall yield. It is demonstrated that largazole is a pro-drug that is activated by removal of the octanoyl residue from the 3-hydroxy-7-mercaptohept-4-enoic acid moiety to generate the active metabolite 2, which is an extraordinarily potent Class I histone deacetylase inhibitor. Synthetic largazole and 2 have been evaluated side-by-side with FK228 and SAHA for inhibition of HDACs 1, 2, 3, and 6. Largazole and largazole thiol were further assayed for cytotoxic activity against a panel of chemoresistant melanoma cell lines, and it was found that largazole is substantially more cytotoxic than largazole thiol; this difference is attributed to differences in the cell permeability of the two substances.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For example, romidepsin and psammaplin A (Figure 15A) contain disulfide bridges that are reduced in the intracellular environment to generate free thiols that are capable of Zn2+-chelation (Figure 15B) [84, 85].”
From Medicinal chemistry advances in targeting class I histone deacetylases (2023) · cites this paper as [85]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, in cellular contexts, the IC50 values of thiol HDACi decrease significantly, due to reduction/hydrolysis of prodrugs. Whereas in vitro experiments that lack reductants or hydrolases show increased IC50 values of such inhibitors [85, 86].”
From Medicinal chemistry advances in targeting class I histone deacetylases (2023) · cites this paper as [85]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Anticancer activities of histone deacetylase inhibitors
Bolden, J. E., Peart, M. J., & Johnstone, R. W. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2133 · Cited by 2,919
Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer
Minucci, S., & Pelicci, P. G. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1779 · Cited by 2,200
Yoshida, M., Kijima, M., Akita, M., & Beppu, T. (1990) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)44885-x · Cited by 1,854
A Mammalian Histone Deacetylase Related to the Yeast Transcriptional Regulator Rpd3p
Taunton, J., Hassig, C. A., & Schreiber, S. L. (1996) · Science · doi:10.1126/science.272.5260.408 · Cited by 1,829
Self-citationHistone-deacetylase inhibitors: novel drugs for the treatment of cancer
Johnstone, R. W. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd772 · Cited by 1,515
Three proteins define a class of human histone deacetylases related to yeast Hda1p
Grozinger, C. M., Hassig, C. A., & Schreiber, S. L. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.9.4868 · Cited by 770
Self-citation(2002) · PubMed · Cited by 732
Histone Deacetylase Inhibitors
Miller, T. A., Witter, D. J., & Belvedere, S. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm0303094 · Cited by 530
Kijima, M., Yoshida, M., Sugita, K., Horinouchi, S., & Beppu, T. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)41547-5 · Cited by 514
UEDA, H., NAKAJIMA, H., HORI, Y., FUJITA, T., NISHIMURA, M., GOTO, T., & OKUHARA, M. (1994) · The Journal of Antibiotics · doi:10.7164/antibiotics.47.301 · Cited by 489
Taori, K., Paul, V. J., & Luesch, H. (2008) · Journal of the American Chemical Society · doi:10.1021/ja7110064 · Cited by 428
A new antifungal antibiotic, trichostatin.
TSUJI, N., KOBAYASHI, M., NAGASHIMA, K., WAKISAKA, Y., & KOIZUMI, K. (1976) · The Journal of Antibiotics · doi:10.7164/antibiotics.29.1 · Cited by 341
UEDA, H., MANDA, T., MATSUMOTO, S., MUKUMOTO, S., NISHIGAKI, F., KAWAMURA, I., & SHIMOMURA, K. (1994) · The Journal of Antibiotics · doi:10.7164/antibiotics.47.315 · Cited by 257
Total Synthesis and Molecular Target of Largazole, a Histone Deacetylase Inhibitor
Ying, Y., Taori, K., Kim, H., Hong, J., & Luesch, H. (2008) · Journal of the American Chemical Society · doi:10.1021/ja8013727 · Cited by 222
Total Synthesis of the Antitumor Depsipeptide FR-901,228
Li, K. W., Wu, J. J., Xing, W., & Simon, J. A. (1996) · Journal of the American Chemical Society · doi:10.1021/ja9613724 · Cited by 167
Shigematsu, N., Ueda, H., Takase, S., Tanaka, H., Yamamoto, K., & TADA, T. (1994) · The Journal of Antibiotics · doi:10.7164/antibiotics.47.311 · Cited by 134
Singh, S. B., Zink, D. L., Polishook, J. D., Dombrowski, A. W., Darkin‐Rattray, S. J., Schmatz, D. M., & GOETZ, M. A. (1996) · Tetrahedron Letters · doi:10.1016/0040-4039(96)01844-8 · Cited by 133
Histone deacetylase inhibitors – a new tool to treat cancer
Somech, R., Izraeli, S., & Simon, A. J. (2004) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2004.04.006 · Cited by 109
Nakao, Y., Yoshida, S., Matsunaga, S., Shindoh, N., Terada, Y., Nagai, K., Yamashita, J. K., Ganesan, A., van Soest, R. W. M., & Fusetani, N. (2006) · Angewandte Chemie International Edition · doi:10.1002/anie.200602047 · Cited by 104
Total Synthesis of Spiruchostatin A, a Potent Histone Deacetylase Inhibitor
Yurek‐George, A., Habens, F., Brimmell, M., Packham, G., & Ganesan, A. (2004) · Journal of the American Chemical Society · doi:10.1021/ja039258q · Cited by 102
Yoshida, M., Hoshikawa, Y., Koseki, K., Mori, K., & Beppu, T. (1990) · The Journal of Antibiotics · doi:10.7164/antibiotics.43.1101 · Cited by 101
Spiruchostatins A and B, novel gene expression-enhancing substances produced by Pseudomonas sp.
Masuoka, Y., Nagai, A., Shin‐ya, K., Furihata, K., Nagai, K., Suzuki, K., Hayakawa, Y., & Seto, H. (2001) · Tetrahedron Letters · doi:10.1016/s0040-4039(00)01874-8 · Cited by 100
Yurek‐George, A., Cecil, A., Mo, A. H. K., Wen, S., Rogers, H., Habens, F., Maeda, S., Yoshida, M., Packham, G., & Ganesan, A. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm0703800 · Cited by 85
Histone Deacetylase Inhibitors: Latest Developments, Trends and Prospects
Moradei, O., Maroun, C., Paquin, I., & Vaisburg, A. (2005) · Current Medicinal Chemistry-Anti-Cancer Agents · doi:10.2174/1568011054866946 · Cited by 84
Improved Total Synthesis of the Potent HDAC Inhibitor FK228 (FR-901228)
Greshock, T. J., Johns, D. M., Noguchi, Y., & Williams, R. M. (2008) · Organic Letters · doi:10.1021/ol702957z · Cited by 80
Self-citationTotal Synthesis of the Depsipeptide FR-901375
Chen, Y., Gambs, C., Abe, Y., Paul Wentworth, & Janda, K. D. (2003) · The Journal of Organic Chemistry · doi:10.1021/jo034765b · Cited by 66
Smith, N. D., & Goodman, M. (2003) · Organic Letters · doi:10.1021/ol034025p · Cited by 62
Videnov, G., Kaiser, D., Kempter, C., & Jung, G. (1996) · Angewandte Chemie International Edition in English · doi:10.1002/anie.199615031 · Cited by 60
Synthesis of the thiazoline-based siderophore (S)-desferrithiocin
Mulqueen, G. C., Pattenden, G., & Whiting, D. A. (1993) · Tetrahedron · doi:10.1016/s0040-4020(01)82385-1 · Cited by 53
A new mild method for the synthesis of amidines
Lange, U. E. W., Schäfer, B., Baucke, D., Buschmann, E., & Mack, H. (1999) · Tetrahedron Letters · doi:10.1016/s0040-4039(99)01460-4 · Cited by 51
Jeanguenat, A., & Seebàch, D. (1991) · Journal of the Chemical Society Perkin Transactions 1 · doi:10.1039/p19910002291 · Cited by 49
Phoenistatin, A New Gene Expression-Enhancing Substance Produced by Acremonium fusigerum.
Masuoka, Y., Shin‐ya, K., FURIHATA, K., Nagai, K., Suzuki, K., Hayakawa, Y., & Seto, H. (2001) · The Journal of Antibiotics · doi:10.7164/antibiotics.54.187 · Cited by 14
Research works printed but not linked: 3
- Townsend P. A., 2007, Chemical Biology, 69, 3
- Yurek-George A., 2004, J. Am. Chem. Soc., 126, 1030, 10.1021/ja039258q · DOI
- Furumai R., 2002, Cancer Res., 62, 4916
Cited by
Chemical phylogenetics of histone deacetylases
Bradner, J. E., West, N., Grachan, M. L., Greenberg, E. F., Haggarty, S. J., Warnow, T., & Mazitschek, R. (2010) · Nature Chemical Biology · doi:10.1038/nchembio.313 · Cited by 720
“Results Comparative study of HDAC inhibitors Recently, we reported the optimization of a miniaturized kinetic assay for the biochemical profiling of HDAC1, HDAC2, HDAC3, HDAC6 and HDAC8 (ref”
MethodSelf-citationOrally Absorbed Cyclic Peptides
Nielsen, D. S., Shepherd, N. E., Xu, W., Lucke, A. J., Stoermer, M. J., & Fairlie, D. P. (2017) · Chemical Reviews · doi:10.1021/acs.chemrev.6b00838 · Cited by 445
Bio-mining the microbial treasures of the ocean: New natural products
Imhoff, J. F., Labes, A., & Wiese, J. (2011) · Biotechnology Advances · doi:10.1016/j.biotechadv.2011.03.001 · Cited by 346
“Largazole belongs to the histone deacetylase inhibitors (Taori et al., 2008; Bowers et al., 2008).”
BackgroundMuscarine, imidazole, oxazole, and thiazole alkaloids
Jin, Z. (2011) · Natural Product Reports · doi:10.1039/c0np00074d · Cited by 311
Structure, mechanism, and inhibition of histone deacetylases and related metalloenzymes
Lombardi, P. M., Cole, K. E., Dowling, D. P., & Christianson, D. W. (2011) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2011.08.004 · Cited by 277
“The resulting largazole thiol is a potent inhibitor of several HDAC isozymes [48, 49], and modification of the depsipeptide skeleton yields analogues that are even more potent inhibitors than largazole itself [50•].”
Background
Metadata
- Authors
- Bowers, A., West, N., Taunton, J., Schreiber, S. L., Bradner, J. E., & Williams, R. M.
- Affiliations
- Broad Institute (US)
- Venue
- Journal of the American Chemical Society
- Publisher
- American Chemical Society (ACS)
- Published
- 2008-07-19
- Volume
- 130
- Issue
- 33
- Pages
- 11219-11222
- ISSN
- 0002-7863 (ISSN-L)
- 1520-5126
- PMC
- PMC3090445
- OpenAlex
- W2082971158
- Cited by
- 165
- References
- 33
- Citations by year
- 2026: 1 · 2025: 3 · 2024: 2 · 2023: 8 · 2022: 3 · 2021: 10 · 2020: 3 · 2019: 9 · 2018: 6 · 2017: 12 · 2016: 9 · 2015: 12 · 2014: 13 · 2013: 10 · 2012: 10
- FWCI
- 7.82
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of the American Chemical Society (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Wellcome Trust
- National Institutes of Health (1p41gm049631-01, n01co12400-79-0-22)
- National Cancer Institute (N01CO12400, N01-CO-012400, K08CA128972, R01CA152314)
- National Institute of General Medical Sciences (GM49631)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Histone Deacetylase Inhibitors Research
- Physical Sciences › Chemistry › Organic Chemistry › Heterocyclic Compound Synthesis and Bioactivity
- Physical Sciences › Chemistry › Organic Chemistry › Isoquinoline Alkaloid Synthesis
- Keywords
- largazole, total synthesis, prodrugs, class I histone deacetylase inhibitors, romidepsin, vorinostat, HDAC1, HDAC2, HDAC3, HDAC6, cytotoxicity, membrane permeability
- MeSH terms
- Vorinostat, Dose-Response Relationship, Drug, Drug Screening Assays, Antitumor, Enzyme Inhibitors, Humans, Hydroxamic Acids, Molecular Conformation, Stereoisomerism, Structure-Activity Relationship, Sulfhydryl Compounds, Thiazoles, Cell Line, Tumor, Depsipeptides, Cell Proliferation, Histone Deacetylase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.